India News: NEW DELHI: Plasma therapy on Covid-19 patients has not been found effective in reducing the progression to severe disease or death and is likely to be.
Top experts finds no proof baricitinib works against Covid
SECTIONS
Share
Synopsis
Experts are of the view that the clinicians can use it in their wisdom, but decided against recommending the drug in the national guidelines.
Getty Images
A top-level expert panel on Covid-19 has found the evidence of efficacy in fighting Covid-19 in drug baricitinib inconclusive and withheld approval of the drug for clinical management protocol in India.
In a meeting held on Wednesday to review the evidence, the Indian Council of Medical Research (ICMR) decided against recommending the drug in the clinical management protocol. While the panel was also supposed to take a decision on the use of plasma therapy, the matter could not be taken up.
»
Bharat Biotech s COVAXIN reportedly recommended by expert panel for phase 2 and 3 clinical trials on 2-18 year-olds
Bharat Biotech s COVAXIN reportedly recommended by expert panel for phase 2 and 3 clinical trials on 2-18 year-olds
PTIMay 13, 2021, 11:48 IST
Business Insider
Covaxin was on Tuesday recommended by an expert panel for
phase II/III
The trial will take place in 525 subjects at various sites, including
AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur. The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (
CDSCO) on Tuesday deliberated upon Hyderabad-based
Bharat Biotech s application seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs in children aged 2 to 18 years.
Representative image
NEW DELHI: In the wake of a rapid spread of Covid-19 infection, the Indian Council of Medical Research (ICMR) has altered its testing strategy to recommend increased use of Rapid Antigen Tests (RAT), mainly to upscale field testing to detect cases early and isolate them to reduce transmission.
The ICMR is not altering its view that an RT-PCR is the gold standard, but feels that a higher use of RAT will be useful in the context of a high number of cases and the need to check both clusters and more spread out populations in rural areas. This would mean a change in the 70:30 ratio of RT-PCR to RAT as has been recommended so far.
ICMR for more Rapid Antigen Tests use to scale up testing
SECTIONS
Share
Synopsis
The ICMR is not altering its view that an RT-PCR is the gold standard, but feels that a higher use of RAT will be useful in the context of a high number of cases and the need to check both clusters and more spread out populations in rural areas. This would mean a change in the 70:30 ratio of RT-PCR to RAT as has been recommended so far.
Agencies
(This story originally appeared in on May 12, 2021)In the wake of a rapid spread of Covid-19 infection, the Indian Council of Medical Research (ICMR) has altered its testing strategy to recommend increased use of Rapid Antigen Tests (RAT), mainly to upscale field testing to detect cases early and isolate them to reduce transmission.